New Anti-CGRP in France: Estimated Financial Impact of Eptinezumab in Hospitals, a Prospective Stake

Author(s)

Cartolano P1, Tano M2, Siorat V3, Fusier I4, Moracchini M5, Parent de Curzon O3, Paubel P6, Degrassat Theas A2
1General Agency of Equipment and Health Products (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP), Boulogne-Billancourt, France, 2General Agency of Equipment and Health Products (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP) ; Law and Health Economics Department, Faculty of Pharmacy & Health Law Institute (INSERM UMR S1145) University of Paris Cité, Paris, France, 3General Agency of Equipment and Health Products (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, 4General Agency of Equipment and Health Products (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP), PARIS, France, 5General Agency of Equipment and Health Products (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP), Courbevoie, 92, France, 6General Agency of Equipment and Health Products (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP) ; Law and Health Economics Department, Faculty of Pharmacy & Health Law Institute (INSERM UMR S1145) University of Paris Cité, Paris, Paris, France

OBJECTIVES: Galcanezumab (Emgality®) and fremanezumab (Ajovy®) are subcutaneous (SC) monoclonal antibodies (mAbs) against calcitonin gene-related peptide (CGRP) indicated in chronical migraine treatment. They are not covered by the French national health insurance (NHI) but are available in retail pharmacies (around €250 per month) at the patient’s expense. Eptinezumab (Vyepti®) is a new costly intravenous anti-CGRP that is only available for inpatients, implying hospital-supported costs.

This study aims to determine the financial impact of eptinezumab in French hospitals.

METHODS: The anti-CGRP mAbs costs for migraine care in hospitals were estimated using data from a French national survey on hospital treatment costs, a probable cost scenario, and the medicalized information system program (ePMSI). Medico-economic data come from a systematic review of the literature.

RESULTS: French NHI reimburses between €403 and €470 for a hospital session for migraine care, with an estimate cost of treatment around €173 allocated before eptinezumab launch. However, by taking into account the estimate price of eptinezumab per administration for a 16 800 target population, the approximate annual financial impact for hospitals could be around -16 million € per year, without considering the potential important related medical costs (for hospitalization, consultations in neurology and psychiatry, general practitioner consult, nurse care and emergency).

In addition, referencing eptinezumab might attract the patients treated by the other anti-CGRP mAbs, which might increase this economic impact.

Comparing to the other anti-CGRP mAbs, literature review shows that eptinezumab has an approximatively equal ICER. Despite this, the NICE is the only agency of United Kingdom that supports NHI coverage of this treatment, due to its ability to reduce migraine symptoms faster.

CONCLUSIONS: This case demonstrates the limits of cost-efficient drugs, which are beneficial to society, but whose costs must be supported by the hospital.

Conference/Value in Health Info

2023-11, ISPOR Europe 2023, Copenhagen, Denmark

Value in Health, Volume 26, Issue 11, S2 (December 2023)

Code

EE580

Topic

Economic Evaluation

Topic Subcategory

Budget Impact Analysis, Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Drugs, No Additional Disease & Conditions/Specialized Treatment Areas

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×